CellAegis Devices Inc. - Media Coverage
RSK Medical and CellAegis Devices partner in the Canadian Health Care Market to improve outcomes for heart attack patients. RSK Medical will distribute CellAegis’ innovative Canadian Medical Technology to reduce Heart Damage.
CellAegis Devices: 2012 Mind to Market Award Finalist
CellAegis autoRIC® Device
European Hospital Early Adopter Program
Safe for your patient, Simple for you!
Preferred Consumables Pricing
Capital Costs Eliminated
Three-year warranty on Device(s)
Better Cath Lab Outcomes, Improved Clinical Benefit
pPCI: Infarct size reduction, MACE & mortality reduced
ePCI: Troponin and MACCE reductions
Coronary Angiogram/TAVR: Significant reduction in CI-AKI
For more information about the autoRIC® Device or to inquire about our European Hospital Early Adopter Program:
Call us: 1-647-722-9601 Email us: email@example.com